ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum
A buzzy RNAi startup is going public via an upsized $446.3 million Nasdaq listing, adding to the biopharma industry's high IPO velocity. ADARx Pharmaceuticals, the latest entrant onto the public markets,
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.